Vaxart, Inc.

VXRT

$0.37

Name : Vaxart, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $88,822,120.00

EPSttm : -0.22

Vaxart, Inc.

$0.37

1.37%

$0.005

Float Short %

9.33

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.02

EPS Last/This Y

0.04

EPS This/Next Y

-0.05

Price

0.37

Target Price

4.67

Analyst Recom

Performance Q

-15.61

Relative Volume

Beta

1.14

Ticker: VXRT

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-13	VXRT	0.3639	N/A	N/A	0
2025-11-14	VXRT	0.39	N/A	N/A	0
2025-11-17	VXRT	0.3975	N/A	N/A	0
2025-11-18	VXRT	0.3983	N/A	N/A	0
2025-11-19	VXRT	0.38	N/A	N/A	0
2025-11-20	VXRT	0.3662	N/A	N/A	0
2025-11-21	VXRT	0.3591	N/A	N/A	0
2025-11-24	VXRT	0.3616	N/A	N/A	0
2025-11-25	VXRT	0.3573	N/A	N/A	0
2025-11-26	VXRT	0.36	N/A	N/A	0
2025-12-01	VXRT	0.3795	0.07	0.00	2168
2025-12-02	VXRT	0.3788	0.07	0.00	2168
2025-12-03	VXRT	0.3613	0.07	0.00	2168
2025-12-04	VXRT	0.362	0.07	0.00	2168
2025-12-05	VXRT	0.3664	0.07	0.00	2168
2025-12-08	VXRT	0.366	0.07	0.00	2168
2025-12-09	VXRT	0.3646	0.07	0.00	2168
2025-12-10	VXRT	0.3659	N/A	N/A	0
2025-12-11	VXRT	0.362	N/A	N/A	0
2025-12-12	VXRT	0.37	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-13	VXRT	0.36	-5.6	-	-0.29
2025-11-14	VXRT	0.37	-5.6	-	-0.29
2025-11-17	VXRT	0.41	-5.6	-	-0.29
2025-11-18	VXRT	0.39	-5.6	-	-0.29
2025-11-19	VXRT	0.39	-5.6	-	-0.29
2025-11-20	VXRT	0.39	-5.6	-	-0.29
2025-11-21	VXRT	0.38	-5.6	-	-0.29
2025-11-24	VXRT	0.36	-5.6	-	-0.29
2025-11-25	VXRT	0.36	-5.6	-	-0.29
2025-11-26	VXRT	0.35	-5.6	-	-0.29
2025-12-01	VXRT	0.37	-5.6	-	-0.29
2025-12-02	VXRT	0.38	-5.6	-	-0.29
2025-12-03	VXRT	0.38	-5.6	-	-0.29
2025-12-04	VXRT	0.38	-5.6	-	-0.29
2025-12-05	VXRT	0.37	-5.6	-	-0.29
2025-12-08	VXRT	0.36	-5.6	-	-0.29
2025-12-09	VXRT	0.37	-5.6	-	-0.29
2025-12-10	VXRT	0.37	-5.6	-	-0.29
2025-12-11	VXRT	0.36	-5.6	-	-0.29
2025-12-12	VXRT	0.37	-5.6	-	-0.29
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="VXRT" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

4.29

Institutional Transactions

Beta

1.14

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.5

Max Drawdown 5-Year %

-98.7

Target Price

4.67

P/E

Forward P/E

PEG

P/S

1.54

P/B

1.6

P/Free Cash Flow

EPS

-0.26

Average EPS Est. Cur. Y

-0.29

EPS Next Y. (Est.)

-0.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-216.4

Return on Equity vs Industry %

-201.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”VXRT” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Vaxart, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 105

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

stock quote shares VXRT – Vaxart, Inc. Stock Price stock today

news today VXRT – Vaxart, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VXRT – Vaxart, Inc. yahoo finance google finance

stock history VXRT – Vaxart, Inc. invest stock market

stock prices VXRT premarket after hours

ticker VXRT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VXRT

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y